Optimizing the Use of Methadone in Newborn Infants

我们正在提交一份更新K24中期职业发展奖的提案，以支持John N.货车登安克，医学博士，博士货车den Anker博士是一名获得委员会认证的儿科医生，同时也获得了临床药理学认证;他是全球仅有的30名拥有这一双重认证的儿科医生之一，也是其中仅有的两名新生儿医生之一。货车den Anker博士于2002年转到国家儿童医学中心（CNMC），成为儿科临床药理学主任，目前是乔治华盛顿大学医学与健康科学学院（GWU）的儿科、药理学和生理学教授。自2005年以来，已经提供了重要的机构和部门承诺，包括财政支持和捐赠主席（埃文和辛迪琼斯儿科临床药理学教授），以建立一个首屈一指的学术儿科临床研究计划。货车登·安克医生目前是私家侦探。美国国立卫生研究院为支持他的药理学研究而提供的一些外部资助。他的专长是发育和新生儿药理学领域，主要关注肾功能对新生儿常用药物临床药代动力学的影响。他的第一个K24奖（2004-2009年）为他提供了机会，以获得在人口药代动力学和药物基因组学的一般方面的技能，并指导3-4名初级教师在儿科药理学研究。在这项提案中，他计划继续指导3-4名在艾滋病毒/艾滋病、精神病学和麻醉学领域进行药理学研究的初级教员。此外，他将进行一项研究项目，重点是开发新生儿和幼儿美沙酮给药的药代动力学模型，该模型将纳入与美沙酮药代动力学相关的发育变化（CYP 2B 6活性和肾功能）和药物遗传学信息（CYP 2B 6基因）。拟议调查的长期目标是提高新生儿和幼儿使用美沙酮的安全性和有效性。

We are submitting a proposal for a renewal of a K24 Mid-Career development Award to support the efforts of John N. van den Anker, M.D., Ph.D. Dr. van den Anker is a Board Certified Pediatrician who is also certified in Clinical Pharmacology; he is one of the only 30 pediatricians world-wide who has this dual certification and is one of the only two Neonatologists among them. Dr. van den Anker moved to Children's National Medical Center (CNMC) in 2002 to become Director of Pediatric Clinical Pharmacology, and he is currently Professor of Pediatrics, Pharmacology & Physiology at the George Washington University School of Medicine and Health Sciences (GWU). Significant institutional and departmental commitments, including financial support and an endowed Chair (Evan and Cindy Jones Professor of Pediatric Clinical Pharmacology) since 2005 have been provided to build a premier academic pediatric clinical research program. Dr. van den Anker is currently the P.I. of a number of external NIH grants in support of his pharmacological research. His expertise is in the area of developmental and neonatal pharmacology, primarily focusing on the effect of renal function on clinical pharmacokinetics of frequently used medicines in the neonate. His first K24 award (2004-2009) offered him the opportunity to gain skills in the general aspects of population pharmacokinetics and pharmacogenomics and to mentor 3-4 junior faculty members in pediatric pharmacology research. In this proposal, he plans to continue mentoring 3-4 junior faculty members who are conducting pharmacological studies in the areas of HIV/AIDS, psychiatry and anesthesiology. In addition, he will perform a research project that will focus on the development of a pharmacokinetic model for methadone dosing in neonates and young infants that will incorporate developmental changes (CYP2B6 activity and renal function) and pharmacogenetic information (CYP2B6 gene) relevant to methadone pharmacokinetics. The long-term goal of the proposed investigation is to improve the safe and effective use of methadone in neonates and young infants.